Navigation Links
ADVENTRX Submits Exelbine™ New Drug Application
Date:11/3/2010

SAN DIEGO, Nov. 3, 2010 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate ANX-530 (vinorelbine injectable emulsion), or Exelbine.

"Our Exelbine submission includes twelve months of site-specific stability data from our intended commercial manufacturer, which fulfills a request communicated to us by the FDA earlier this year.  We believe this submission will be accepted for review in early 2011 and we look forward to working with the Agency toward our first product approval," said Brian M. Culley, Chief Executive Officer of ADVENTRX.

ADVENTRX retains exclusive worldwide rights to Exelbine, other than in China, Hong Kong, Macau and Taiwan.  In March 2010, the FDA conditionally accepted "Exelbine" as the proposed proprietary name for ANX-530.  In October 2010, patent claims related to Exelbine were allowed by the United States Patent and Trademark Office.  These patent claims, when issued, will extend into 2024.  

ADVENTRX is seeking approval of Exelbine for the same indications as Navelbine®, a branded formulation of vinorelbine, including non-small cell lung cancer.  ADVENTRX submitted the NDA as a 505(b)(2) application that relies in part on the FDA's findings of safety and effectiveness of a reference drug.  The Company's 505(b)(2) NDA submission includes data from one clinical bioequivalence study designed to assess the pharmacokinetic equivalence of Exelbine and Navelbine, the reference drug.  In this clinical bioequivalence study, Exelbine and the reference drug were determined by ADVENTRX to be bioequivalent.  

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are bein
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
5. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
6. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
8. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
9. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
10. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
11. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... N.J. , Jan. 15, 2014  Celsion Corporation ... announced that it has received commitments from institutional ... million of the Company,s common stock in an ... health care fund. The Company entered ... to which the Company agreed to sell an ...
(Date:1/15/2014)... -- BreedIT Corp (OTC: BRDT), through its ... highly sophisticated agro-breeding solutions for plant breeders and researchers, ... board of directors appointed chemistry and pharmaceutical industry expert ... of the board. From 1975 to 2012, ... Ltd (NYSE: TEVA ) and its subsidiaries ...
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ... VSRNAs are of molecular size less than 10 bps, ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... RALEIGH, N.C., Feb. 17, 2011 BioDelivery Sciences International, ... enrollment of its Phase 3 trial assessing the efficacy ... moderate to severe chronic pain is on schedule, with ... (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO) "We are very pleased ...
... Feb. 17, 2011 Reportlinker.com announces ... is available in its catalogue: ... - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones ... http://www.reportlinker.com/p0397051/Anti-Bacterials-Market-to-2016---Cephalosporins-Penicillins-Macrolides-and-Fluoroquinolones-to-Drive-the-Anti-Bacterials-Market.html ...
Cached Medicine Technology:BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule 2BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule 3Reportlinker Adds Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market 2Reportlinker Adds Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market 3
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... U.S. News Media Group and the National Committee ... edition of America,s Best Health Insurance Plans on ... open-enrollment season, when Americans nationwide prepare to select their ... provides consumers with comprehensive rankings and important detailed information ...
... Nov. 12 Bausch & Lomb, the global eye health ... its Board of Directors. , Mr. Hassan was chairman ... by Merck & Co., Inc. on November 3. Before joining ... as chairman and CEO (from 2001 to 2003) of Pharmacia ...
... her bout with H1N1, made all the worse by chronic asthma ... been following the news about the H1N1 swine flu with some ... And from the many hours talking with infectious-disease specialists, I knew ... might be another flu pandemic, but when . , The ...
... ... holiday recipe for Holly Jolly Biscotti, which showcases the peak-season flavors of Texas citrus and ... to promote a good-for-you diet throughout the holidays not just for yourself, but everyone on ... Dallas, ...
... ... of Fresh Throne are the quickest way to keep any bathroom fit for royalty. During product ... ... brand new, all natural spray shield aimed at protecting against horrible bathroom odors. Just a ...
... 11 /PRNewswire-FirstCall/ - Nuvo Research Inc. (TSX: NRI), a ... development of drug products that are delivered to and ... delivery technologies, and on the development of its immune ... agreement for Oxoferin(TM), its topical wound healing agent, and ...
Cached Medicine News:Health News:U.S. News Media Group and NCQA Release 2009-10 Rankings of America's Best Health Insurance Plans 2Health News:U.S. News Media Group and NCQA Release 2009-10 Rankings of America's Best Health Insurance Plans 3Health News:U.S. News Media Group and NCQA Release 2009-10 Rankings of America's Best Health Insurance Plans 4Health News:Fred Hassan Joins Bausch & Lomb Board of Directors 2Health News:My 10-Day Ordeal With the Swine Flu 2Health News:My 10-Day Ordeal With the Swine Flu 3Health News:My 10-Day Ordeal With the Swine Flu 4Health News:Dip into a Healthy Holiday with the Taste of Texas Oncology's Holly Jolly Biscotti 2Health News:Dip into a Healthy Holiday with the Taste of Texas Oncology's Holly Jolly Biscotti 3Health News:Dip into a Healthy Holiday with the Taste of Texas Oncology's Holly Jolly Biscotti 4Health News:Fresh Throne Eco-Friendly Bathroom Spray Celebrates Launch by Donating to Salvation Army 2Health News:Nuvo research provides WF10 licensing and development update 2Health News:Nuvo research provides WF10 licensing and development update 3Health News:Nuvo research provides WF10 licensing and development update 4Health News:Nuvo research provides WF10 licensing and development update 5
CDIs Chin Support Bandage is ideal for Submental Liposuction, Chin Implants and all other facial procedures requiring support. Adjustable Velcro® top and posterior band secures placement....
Four way compression with five contact closures...
Applies pressure on scalp to stretch it before surgery...
Facial Mask...
Medicine Products: